Agrylin (anagrelide hydrochloride) NDC 54092-063

NDC codes

FDA NDC Directory

Product NDC (as listed)54092-063Labeler and product segments. Claims need a package NDC.

Product NDC at billing width54092-0063Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
54092-063-01	54092006301	100 CAPSULE in 1 BOTTLE (54092-063-01)Marketed from Mar 14, 1997

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Agrylin
Generic name (nonproprietary): anagrelide hydrochloride
Active ingredients: Anagrelide hydrochloride anhydrous — .5 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Takeda Pharmaceuticals America, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020333
Marketing start: Mar 14, 1997
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Platelet Production (Physiologic effect)Phosphodiesterase 3 Inhibitors (Mechanism)
Identifiers: Product ID 54092-063_80829f8c-c5ee-4e37-b5af-1b0e4e4dd5bdSPL ID 80829f8c-c5ee-4e37-b5af-1b0e4e4dd5bdSPL set ID cb960074-99c1-4a73-941f-f0644a7ec219RxCUI 597850, 597857UNII VNS4435G39UPC 0354092063017
Pharmacologic class: Platelet-reducing Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N454092006301 followed by a unit qualifier and the quantity

Package 54092-0063-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 8, 2026.

Indications (excerpt from the label)

AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. AGRYLIN is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)